Registers› Irish medicines ›Baxter Holding B.V.

Medicines register · Ireland

Baxter Holding B.V. — licensed medicines

74 medicines held by Baxter Holding B.V. on the Irish market, from the HPRA register.

Source: HPRA open dataset ("Authorised or Transfer Pending Products"), CC BY 4.0. Complete coverage — all 10,296 authorised products are in this register. Synced 09 Oct 2026, 03:22 UTC

Narrow the register Reset

Search within results

Matches brand name, active substance, licence holder and licence number.

Browse by first letter

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0–9

Medicine

Active substance

Licence holder

Status

Aciclovir 25mg/ml Concentrate for solution for infusion PA2299/041/001

Aciclovir

Baxter Holding B.V.

Not marketed

ARTISS Solutions for Sealant, deep frozen PA2299/026/001

Human fibrinogen, Human thrombin, Calcium chloride, Aprotinin

Baxter Holding B.V.

Marketed

Brevibloc Premixed 10 mg/ml solution for Infusion PA2299/021/002

Esmolol Hydrochloride

Baxter Holding B.V.

Marketed

Brevibloc Premixed 10 mg/ml Solution for Injection PA2299/021/001

Esmolol Hydrochloride

Baxter Holding B.V.

Marketed

Bupivacaine 2.5 mg/ml Solution for Injection PA2299/035/001

Bupivacaine hydrochloride, monohydrate

Baxter Holding B.V.

Not marketed

Bupivacaine 5 mg/ml Solution for Injection PA2299/035/002

Bupivacaine hydrochloride, monohydrate

Baxter Holding B.V.

Marketed

Caelyx pegylated liposomal 2 mg/ml concentrate for solution for infusion EU/1/96/011/001-004

DOXORUBICIN HYDROCHLORIDE

Baxter Holding B.V.

—

Cernevit, Powder for Solution for Injection or Infusion PA2299/019/001

Retinol palmitate, Cholecalciferol, Dl-a-tocopherol, Ascorbic acid, Cocarboxylase tetrahydrate

Baxter Holding B.V.

Marketed

Chlorhexidine acetate 0.015% w/v and Cetrimide 0.15% w/v Irrigation solution PA2299/005/001

Chlorhexidine acetate, Cetrimide

Baxter Holding B.V.

Not marketed

Chlorhexidine Acetate BP 0.05% w/v Irrigation solution PA2299/004/001

Chlorhexidine acetate

Baxter Holding B.V.

Marketed

CLINIMIX N14G30E, solution for infusion PA2299/020/001

L-leucine, L-phenylalanine, L-methionine, L-isoleucine, L-valine

Baxter Holding B.V.

Marketed

Compound Sodium Lactate Solution for Infusion BP PA2299/012/001

Sodium chloride, Potassium chloride, Calcium chloride dihydrate, Sodium lactate

Baxter Holding B.V.

Marketed

Dexmedetomidine 100 micrograms/ml concentrate for solution for infusion PA2299/050/001

Dexmedetomidine hydrochloride

Baxter Holding B.V.

Not marketed

Endoxana Coated Tablets 50 mg PA2299/027/003

Cyclophosphamide monohydrate

Baxter Holding B.V.

Marketed

Endoxana Injection 1000 mg Powder for Solution for Injection PA2299/027/002

Cyclophosphamide

Baxter Holding B.V.

Marketed

Endoxana Injection 500 mg Powder for Solution for Injection PA2299/027/001

Cyclophosphamide

Baxter Holding B.V.

Marketed

Eribulin Baxter 0.44 mg/mL solution for injection EU/1/24/1819/001

Eribulin mesylate

Baxter Holding B.V.

—

Finomel Emulsion for Infusion PA2299/044/002

Glycine, Alanine, Arginine, Histidine, Isoleucine

Baxter Holding B.V.

Marketed

Finomel Peri Emulsion for Infusion PA2299/044/001

Alanine, Arginine, Glycine, Histidine, Isoleucine

Baxter Holding B.V.

Marketed

Fluconazole 2 mg/ml solution for infusion PA2299/033/001

Fluconazole

Baxter Holding B.V.

Marketed

Furosemide 10 mg/ml Solution for Injection PA2299/036/001

Furosemide

Baxter Holding B.V.

Not marketed

Glucose 10% w/v Solution for Infusion PA2299/003/002

Glucose

Baxter Holding B.V.

Marketed

Glucose 5% w/v Intravenous Infusion BP, polyolefin/polyamide bag PA2299/003/001

Glucose

Baxter Holding B.V.

Marketed

Heparin Sodium BP 1000 IU/l in 0.9% w/v Sodium Chloride IV Infusion PA2299/014/001

Heparin sodium, Sodium chloride, Disodium phosphate dodecahydrate, Citric acid monohydrate

Baxter Holding B.V.

Marketed

Heparin Sodium BP 2000 IU/l in 0.9 % w/v Sodium Chloride IV infusion PA2299/014/002

Citric acid monohydrate, Disodium phosphate dodecahydrate, Sodium chloride, Heparin sodium

Baxter Holding B.V.

Marketed

Maintelyte solution for infusion PA2299/045/001

Sodium chloride, GLUCOSE MONOHYDRATE PH. EUR., Sodium acetate, trihydrate, POTASSIUM CHLORIDE PH. EUR., MAGNESIUM CHLORIDE HEXAHYDRATE PH. EUR.

Baxter Holding B.V.

Marketed

Mannitol 10% Solution for Infusion BP PA2299/006/001

Mannitol

Baxter Holding B.V.

Marketed

Mannitol 15% w/v solution for infusion PA2299/006/002

Mannitol

Baxter Holding B.V.

Marketed

Mitoxana 1 g Powder for Sterile Concentrate PA2299/028/001

Ifosfamide

Baxter Holding B.V.

Marketed

Mitoxana 2 g powder for sterile concentrate PA2299/028/002

Ifosfamide

Baxter Holding B.V.

Marketed

Numeta G13%E Preterm emulsion for infusion PA2299/030/003

Alanine, Arginine, Aspartic Acid, Cysteine, Glutamic acid

Baxter Holding B.V.

Marketed

Numeta G16%E emulsion for infusion PA2299/030/001

Alanine, Arginine, Aspartic Acid, Cysteine, Glutamic acid

Baxter Holding B.V.

Marketed

Numeta G19%E emulsion for infusion PA2299/030/002

Methionine, Ornithine hydrochloride, Phenylalanine, Proline, Serine

Baxter Holding B.V.

Marketed

Ondansetron 2mg/ml Solution for Injection PA2299/037/001

Ondansetron

Baxter Holding B.V.

Marketed

Pemetrexed Baxter 100 mg powder for concentrate for solution for infusion EU/1/22/1705/001

Pemetrexed disodium heptahydrate

Baxter Holding B.V.

—

Pemetrexed Baxter 500 mg powder for concentrate for solution for infusion EU/1/22/1705/002

Pemetrexed disodium heptahydrate

Baxter Holding B.V.

—

Plasma-Lyte 148 & Glucose 5% w/v solution for infusion PA2299/007/001

Glucose monohydrate, Sodium chloride, Potassium chloride, Magnesium chloride hexahydrate, Sodium acetate trihydrate

Baxter Holding B.V.

Marketed

Plasma-Lyte 148 (pH 7.4) solution for infusion PA2299/032/001

Sodium chloride, Potassium chloride, Magnesium chloride hexahydrate, Sodium acetate trihydrate, Sodium gluconate

Baxter Holding B.V.

Marketed

Potassium Chloride 0.15% w/v & Sodium Chloride 0.9% w/v Solution for Infusion - BP PA2299/010/002

Potassium chloride, Sodium chloride

Baxter Holding B.V.

Marketed

Potassium Chloride 0.15% w/v and Glucose 5% w/v Solution for Infusion BP PA2299/009/002

Potassium chloride, Glucose

Baxter Holding B.V.

Marketed

Potassium Chloride 0.15% w/v, Sodium Chloride 0.18% w/v, Glucose 4% w/v Solution for Infusion PA2299/001/002

Potassium chloride, Sodium chloride, Glucose anhydrous

Baxter Holding B.V.

Marketed

Potassium Chloride 0.3 % w/v and Glucose 5% w/v Solution for Infusion BP PA2299/009/001

Potassium chloride, Glucose (as monohydrate)

Baxter Holding B.V.

Marketed

Potassium Chloride 0.3% w/v & Sodium Chloride 0.9% w/v Solution for Infusion BP PA2299/010/001

Potassium chloride, Sodium chloride

Baxter Holding B.V.

Marketed

Potassium Chloride 0.3% w/v and Sodium Chloride 0.18% w/v in Glucose 4% w/v Intravenous Infusion BP (Viaflo Container) PA2299/001/001

Potassium chloride, Sodium chloride, Glucose monohydrate

Baxter Holding B.V.

Marketed

Primene 10% Solution for Infusion PA2299/018/001

L-isoleucine, L-leucine, L-valine, L-lysine, L-methionine

Baxter Holding B.V.

Marketed

Propofol 10 mg/ml Emulsion for injection/infusion PA2299/038/001

Propofol

Baxter Holding B.V.

Marketed

Propofol 20 mg/ml Emulsion for injection/infusion PA2299/038/002

Propofol

Baxter Holding B.V.

Marketed

Ringer’s Solution for Infusion, Viaflo container PA2299/011/001

Sodium chloride, Potassium chloride, Calcium chloride dihydrate

Baxter Holding B.V.

Marketed

Sevoflurane Baxter, 100%, inhalation vapour, liquid PA2299/031/001

Sevoflurane

Baxter Holding B.V.

Marketed

Sodium Chloride 0.18% w/v and Glucose 4.0% w/v Intravenous Infusion BP, (Viaflo Container) PA2299/008/005

Sodium chloride, Anhydrous glucose

Baxter Holding B.V.

Marketed

Cite this view

Priya Life Science (2026). Irish Medicines Register, filtered. Derived from the HPRA open dataset. Retrieved 9 October 2026. https://priyalifescience.com/medicines/company/baxter-holding-b-v

Download this register

GET /api/export.php?register=medicines-ie&format=csv Try the JSON export →

Regulatory information only — not medical advice. For the authoritative record see the HPRA register directly.